e-learning
resources
Munich 2006
Monday 04.09.2006
Pulmonary arterial hypertension: from bench back to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Response of plasma von Willebrand factor to systemic endothelial injury in pulmonary arterial hypertension
D. Montani, R. Souza, M. Wolf, O. Sitbon, G. Simonneau, M. Humbert (Clamart, France)
Source:
Annual Congress 2006 - Pulmonary arterial hypertension: from bench back to bedside
Session:
Pulmonary arterial hypertension: from bench back to bedside
Session type:
Poster Discussion
Number:
3149
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Montani, R. Souza, M. Wolf, O. Sitbon, G. Simonneau, M. Humbert (Clamart, France). Response of plasma von Willebrand factor to systemic endothelial injury in pulmonary arterial hypertension. Eur Respir J 2006; 28: Suppl. 50, 3149
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
The physiology of breathlessness
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Elevated Von Willebrand Factor expression in the activated pulmonary endothelium of chronic thromboembolic pulmonary hypertension patients enhances platelet adhesion.
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
Expression of CD 34 and von Willebrand factor in pulmonary endothelium
Source: Eur Respir J 2001; 18: Suppl. 33, 243s
Year: 2001
Microalbuminuria and von Willebrand factor antigen (vWF) as markers of endothelial dysfunction in COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 123s
Year: 2004
Pulmonary artery endothelial cell secretion of factor VIII
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Endothelin, endothelial cells and von Willenbrandt factor in peripheral blood in asthma patients
Source: Eur Respir J 2003; 22: Suppl. 45, 77s
Year: 2003
Serum levels of vascular endothelial growth factor in patients with systemic sclerosis. Correlation with systolic pressure in the pulmonary artery
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Changes of plasma von Willebrand factor in patients with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 138s
Year: 2007
Increased platelet reactivity and thrombogenesis in pulmonary arterial hypertension subgroups
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
Nerve growth factor expression and function in pulmonary arterial hypertension
Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Year: 2010
PP308 – Endothelial injury in Chronic Obstructive Pulmonary Disease assessed by microalbuminuria (MAB) and von Willebrand factor levels and activity
Source: ERS Lung Science Conference 2021
Year: 2021
Circulating angiopoietins in idiopathic pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Endothelin-1 and coagulation parameters in pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 25s
Year: 2002
Possible role of imatinib in clinical pulmonary veno-occlusive disease
Source: Eur Respir J 2008; 32: 232-235
Year: 2008
Dual mechanism of platelet-derived growth factor (PDGF)-receptor: Contribution of vascular response to the pathogenesis of pulmonary hypertension (PH)
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Elevated factor FVIII:C levels in patients with pulmonary hypertension: a marked of endothelial dysfunction?
Source: Eur Respir J 2003; 22: Suppl. 45, 584s
Year: 2003
P-selectin and PDGF serum levels might not be related to idiopathic pulmonary arterial hypertension and schistosomiasis
Source: Annual Congress 2010 - Pulmonary circulation III
Year: 2010
Expression of platelet derived-growth factor (PDGF) in remodelled pulmonary arteries of COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 25s
Year: 2002
VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction
Source: Eur Respir J 2006; 28: Suppl. 50, 548s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept